Spotting a gem from transpacific biotech, AstraZeneca pays $25M cash to pick up a preclinical bispecific antibody
Looking to expand its oncology pipeline, AstraZeneca has turned to the east to pick up a next-gen drug against an emerging target.
Harbour BioMed, a Shanghai-based outfit that also has sizable teams in Cambridge, MA and Rotterdam, Netherlands, is out-licensing its CLDN18.2xCD3 bispecific antibody to AstraZeneca in exchange for $25 million upfront and up to $325 million in milestones plus royalties.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.